About
Independent HEOR advisor and evidence architecture practice
Independent practice
Outcomes Analytica is my independent advisory practice. I work with pharmaceutical and biotech teams on HEOR, market access, and evidence architecture.
I often act as a technical discussion partner for market access and HEOR professionals who are carrying complex evidence questions internally and need an outside view that understands science, business strategy, and internal politics.
My work usually sits where regulatory strategy and HTA requirements meet: target product profile, endpoint and COA strategy, endpoint design optimization, early economic case, embedded HEOR support, JCA/HTA readiness, and dossier defence.
Before founding the practice in 2019, I held global HEOR roles in oncology and ATMP/gene therapy. My work now stays deliberately focused: a small number of projects, direct involvement, and practical evidence decisions that asset teams can use.
MPhil Health Economics, University of Oslo. Twenty-two peer-reviewed publications, including BMJ Open, European Journal of Health Economics, Quality of Life Research, and Journal of Medical Economics.
Where I usually help
Most engagements sit inside an asset team rather than outside it. The task is to make the value story, evidence plan, and payer logic coherent before clinical, regulatory, commercial, or access decisions harden.
Typical roles include early pipeline asset shaping, embedded strategic HEOR support, target product profile development, endpoint design at the regulation/HTA interface, fit-for-purpose PRO and COA strategy, economic model architecture, vendor review, and HTA or JCA preparation.
Selected publications
How engagements work
Advisor and discussion partner
Some clients need a defined deliverable. Others need a technically grounded outside view while they work through decisions internally. I can work both ways.
Embedded HEOR support
When a market access or asset team needs in-house support, I can work as an embedded HEOR advisor: attending core team meetings, pressure-testing decisions, and helping translate evidence strategy into usable internal recommendations.
Regulation and HTA together
The highest leverage is usually before pivotal design is fixed: comparator, endpoint, COA, subgroup, target product profile, and early economic case.
Flexible by scope
Work can be structured as a focused SOW, retainer, day-rate, or embedded role. NDA and sponsor data-handling requirements are standard.
15+ years · 22 peer-reviewed publications · independent since 2019
Independent single-consultant practice. Limited capacity; book early for availability.
Schedule a Call Or by email: